
|Articles|October 28, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Sequencing Agents for the Treatment of Pancreatic NETs
Author(s)Pamela L. Kunz, MD
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).
Advertisement
Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).
Learn more about research into the treatment of pancreatic NETs > >
Articles in this issue
over 11 years ago
Unanswered Questions Regarding the Treatment of Pancreatic NETsover 11 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsover 11 years ago
Research on Epidemiology of GIST Identifies Risk Factorsover 11 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationover 11 years ago
Coping With Comorbidities in Hepatocellular Cancerover 11 years ago
Strategies in Surveillance: Hepatocellular Carcinomaover 11 years ago
Immunotherapy and Viral Therapy for Pancreatic CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















